ICMR To Study How Long Vaccines Will Give Protection

New Delhi : India’s top health research body is all set to study how long Covid-19 vaccine will protect those who are vaccinated and from transmitting the virus to others. The National Institute of Research in TB under the Indian Council of Medical Research (ICMR) has started reviewing a cohort that has received the vaccine to understand the effectiveness of the vaccine.

“Right now it’s slightly premature to answer the question on effectiveness but we are working on it,” Balram Bhargava, DG, Indian Council of Medical Research, told ET. Taking a cue from how the antibody persists post vaccination, the researchers are looking at the data to see the antibody response, protection of antibodies etc. The participants will be followed up for a longer period of time,” said a government official.

Doctors say that many people are hesitant to get Covid-19 vaccine as they wait to learn how long people don’t pass Covid19 if they have been vaccinated.

“We have patients who want to know the effectiveness of the vaccine even as there is evidence that suggests that people who are vaccinated are less likely to have symptomatic infection and less likely transmit. But they are waiting as there is no India specific study so far that gives more confidence to people,” said a senior doctor in a government hospital, requesting anonymity.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’